Fujitsu implemented the platform on quantum computings for fast creation of new drugs

In the middle of March, 2020 Fujitsu signed the partnership agreement with Polaris to implement for the partner the platform for search of drugs on the basis of quantum computings. This solution is designed to help the pharmaceutical companies quicker and with smaller costs to bring the vital drugs to the market. The platform uses a combination of quantum computings (Digital Annealer), machine learning and hybrid modeling on the basis of a quantum and molecular mechanics (QM/MM).

Fujitsu signed the partnership agreement with Polaris to implement for the partner the platform for search of drugs on the basis of quantum computings

The innovation platform will study and reveal the molecules necessary for development of the most perspective drugs. While other approaches allow to estimate tens of millions of molecules, the Polaris platform can browse billions. The quantum Digital Annealer technology developed by Fujitsu works 10,000 times quicker, than any other solution, reducing time necessary for identification of molecules and achievement of the first stages of development of medicine, from two-four years to only eight months, developers claim.

It is supposed that the new platform can revolutionize development process of medicines. The pilot project is aimed at finding medicine for Dengue fever, a widespread disease which leads to infection 100 million people and 22,000 lethal outcomes annually. Treatment of Dengue fever still does not exist therefore Fujitsu and Polaris selected this disease for a pilot project.

It is supposed that the companies will be able to provide candidates for development of medicine by May, 2020 then their partners will be able to pass to the next stage of researches. In parallel both companies together with pharmaceutical partners study other diseases which urgently require treatment.^[1]

Notes